BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Darwish NHE, Sudha T, Godugu K, Bharali DJ, Elbaz O, El-Ghaffar HAA, Azmy E, Anber N, Mousa SA. Novel Targeted Nano-Parthenolide Molecule against NF-kB in Acute Myeloid Leukemia. Molecules 2019;24:E2103. [PMID: 31163672 DOI: 10.3390/molecules24112103] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Schlein LJ, Thamm DH. Review: NF-kB activation in canine cancer. Vet Pathol. [DOI: 10.1177/03009858221092017] [Reference Citation Analysis]
2 Chen M, Qu Y, Yue P, Yan X. The Prognostic Value and Function of HOXB5 in Acute Myeloid Leukemia. Front Genet 2021;12:678368. [PMID: 34421991 DOI: 10.3389/fgene.2021.678368] [Reference Citation Analysis]
3 Bolandi SM, Pakjoo M, Beigi P, Kiani M, Allahgholipour A, Goudarzi N, Khorashad JS, Eiring AM. A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia. Cells 2021;10:2833. [PMID: 34831055 DOI: 10.3390/cells10112833] [Reference Citation Analysis]
4 Poma P, Labbozzetta M, McCubrey JA, Ramarosandratana AV, Sajeva M, Zito P, Notarbartolo M. Antitumor Mechanism of the Essential Oils from Two Succulent Plants in Multidrug Resistance Leukemia Cell. Pharmaceuticals (Basel) 2019;12:E124. [PMID: 31454963 DOI: 10.3390/ph12030124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Peter AE, Sandeep BV, Rao BG, Kalpana VL. Nanotechnology to the Rescue: Treatment Perspective for the Immune Dysregulation Observed in COVID-19. Front Nanotechnol 2021;3:644023. [DOI: 10.3389/fnano.2021.644023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Pai P, Sukumar S. HOX genes and the NF-κB pathway: A convergence of developmental biology, inflammation and cancer biology. Biochim Biophys Acta Rev Cancer 2020;1874:188450. [PMID: 33049277 DOI: 10.1016/j.bbcan.2020.188450] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
7 Salama L, Pastor ER, Stone T, Mousa SA. Emerging Nanopharmaceuticals and Nanonutraceuticals in Cancer Management. Biomedicines 2020;8:E347. [PMID: 32932737 DOI: 10.3390/biomedicines8090347] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
8 Ren Z, Lv M, Yu Q, Bao J, Lou K, Li X. MicroRNA-370-3p shuttled by breast cancer cell-derived extracellular vesicles induces fibroblast activation through the CYLD/Nf-κB axis to promote breast cancer progression. FASEB J 2021;35:e21383. [PMID: 33629796 DOI: 10.1096/fj.202001430RR] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wei Z, Li C, Zhang Y, Lin C, Zhang Y, Shu L, Luo L, Zhuo J, Li L. Macrophage-Derived IL-1β Regulates Emergency Myelopoiesis via the NF-κB and C/ebpβ in Zebrafish. J Immunol 2020;205:2694-706. [PMID: 33077646 DOI: 10.4049/jimmunol.2000473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Afshari AR, Sanati M, Mollazadeh H, Kesharwani P, Johnston TP, Sahebkar A. Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways. Semin Cancer Biol 2022:S1044-579X(22)00018-9. [PMID: 35115226 DOI: 10.1016/j.semcancer.2022.01.008] [Reference Citation Analysis]
11 Wu LM, Liao XZ, Zhang Y, He ZR, Nie SQ, Ke B, Shi L, Zhao JF, Chen WH. Parthenolide Augments the Chemosensitivity of Non-small-Cell Lung Cancer to Cisplatin via the PI3K/AKT Signaling Pathway. Front Cell Dev Biol 2020;8:610097. [PMID: 33614623 DOI: 10.3389/fcell.2020.610097] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Carlisi D, Lauricella M, D'Anneo A, De Blasio A, Celesia A, Pratelli G, Notaro A, Calvaruso G, Giuliano M, Emanuele S. Parthenolide and Its Soluble Analogues: Multitasking Compounds with Antitumor Properties. Biomedicines 2022;10:514. [PMID: 35203723 DOI: 10.3390/biomedicines10020514] [Reference Citation Analysis]
13 Moujir L, Callies O, Sousa PMC, Sharopov F, Seca AML. Applications of Sesquiterpene Lactones: A Review of Some Potential Success Cases. Applied Sciences 2020;10:3001. [DOI: 10.3390/app10093001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 9.5] [Reference Citation Analysis]
14 Liu AR, Ramakrishnan P. Regulation of Nuclear Factor-kappaB Function by O-GlcNAcylation in Inflammation and Cancer. Front Cell Dev Biol 2021;9:751761. [PMID: 34722537 DOI: 10.3389/fcell.2021.751761] [Reference Citation Analysis]
15 Uddin R, Darwish NHE, Mousa SA. Acute Myeloid Leukemia Mutations and Future Mechanistic Target to Overcome Resistance. Curr Treat Options Oncol 2021;22:76. [PMID: 34213682 DOI: 10.1007/s11864-021-00880-x] [Reference Citation Analysis]
16 Ci T, Zhang W, Qiao Y, Li H, Zang J, Li H, Feng N, Gu Z. Delivery strategies in treatments of leukemia. Chem Soc Rev 2022. [PMID: 35188506 DOI: 10.1039/d1cs00755f] [Reference Citation Analysis]
17 Labbozzetta M, Notarbartolo M, Poma P. Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of View. Int J Mol Sci 2020;21:E3070. [PMID: 32349210 DOI: 10.3390/ijms21093070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
18 Tan Y, Wu Q, Zhou F. Targeting acute myeloid leukemia stem cells: Current therapies in development and potential strategies with new dimensions. Crit Rev Oncol Hematol 2020;152:102993. [PMID: 32502928 DOI: 10.1016/j.critrevonc.2020.102993] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Adebayo IA, Usman AI, Shittu FB, Ismail NZ, Arsad H, Muftaudeen TK, Samian MR. Boswellia dalzielii-Mediated Silver Nanoparticles Inhibited Acute Myeloid Leukemia (AML) Kasumi-1 Cells by Inducing Cell Cycle Arrest. Bioinorg Chem Appl 2020;2020:8898360. [PMID: 33029114 DOI: 10.1155/2020/8898360] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Sztiller-Sikorska M, Czyz M. Parthenolide as Cooperating Agent for Anti-Cancer Treatment of Various Malignancies. Pharmaceuticals (Basel) 2020;13:E194. [PMID: 32823992 DOI: 10.3390/ph13080194] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]